JUNSHI BIO (688180.SH): Tropilimab Monoclonal Antibody Granted Marketing Authorization in the UK, the First and Only Drug for the Treatment of Nasopharyngeal Cancer in the UK.

JUNSHI BIO (688180.SH) announced that its wholly-owned subsidiary, TopAlliance Biosciences Inc., has obtained marketing approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for its product Teripulimab (marketed in the UK as LOQTORZI). The approval allows for the treatment of two indications: Teripulimab in combination with cisplatin and fluorouracil for first-line treatment of recurrent, unresectable or metastatic nasopharyngeal cancer in adults, and Teripulimab in combination with cisplatin and paclitaxel for first-line treatment of unresectable advanced/recurrent or metastatic esophageal squamous cell carcinoma in adults. Teripulimab is the first and only drug approved in the UK for the treatment of nasopharyngeal cancer and the only first-line treatment drug in the UK for unresectable advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression.